Elarex has developed a patented stabilization technology that utilizes viral vectors combined with a proprietary formulation to enable vaccines and biologics to be stored at temperatures up to 40°C, significantly reducing the need for ultra-cold storage. This technology enhances the stability of various therapeutics, including DNA and RNA, facilitating easier distribution and access in diverse healthcare settings.
Funding
$943K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many vaccines and biologics require ultra-cold storage, creating significant logistical challenges and limiting access, especially in resource-limited settings. The need for specialized freezers and temperature-controlled supply chains increases costs and hinders widespread distribution.
Solution
Elarex has developed a patented technology that stabilizes vaccines and biologics, enabling storage at temperatures up to 40°C. This stabilization is achieved through a combination of viral vectors and a proprietary formulation and drying process. The technology enhances the thermal stability of nucleic acids, enzymes, and other bio-therapeutics, facilitating easier distribution and reducing reliance on costly cold-chain infrastructure. The formulation is designed for easy adoption into existing vaccine manufacturing processes without requiring specialized equipment or novel adjuvants.
Target Audience
The primary target audience includes vaccine manufacturers, pharmaceutical companies, and global health organizations seeking to improve the stability and accessibility of vaccines and biologics.
Features
- Patented stabilization technology utilizing viral vectors and a proprietary formulation.
- Enables storage of vaccines and biologics at temperatures up to 40°C.
- Compatible with a wide range of bio-therapeutics, including DNA, RNA, small molecules, and enzymes.
- Simple process that can be easily integrated into existing vaccine manufacturing.
- Components of the formulation are on the FDA's "GRAS" list (Generally Regarded as Safe).
- Demonstrated in vivo efficacy in mice with vaccines stored at elevated temperatures.